Remygen® trial results to be presented in April

The database for Uppsala University Hospital’s ReGenerate-1 trial, which evaluates the safety and efficacy of Diamyd Medical's study drug Remygen[®] in individuals with Type 1 Diabetes, will be locked imminently whereupon the data will be sent to the contract research organization that carries out the statistical analysis. Topline results are expected to be announced in April.“The trial has been received positively by the study participants and we look forward to the results with great interest”, says Per-Ola Carlsson, Professor at Uppsala University and Uppsala University Hospital and